Supply chain complexity means that upper payment limits and Medicare maximum fair prices will fall disproportionately on pharmacies, leading to closures that threaten patient access to care.
Read More
Although the state won FDA approval for its importation program in January 2024, it has yet to implement the program.
Read More
Between November 2022 and June 2023, Amarvel Biotech sold over 200 kilograms of precursor chemicals to U.S. buyers with full knowledge that they would be used to make fentanyl.
Read More
Our analysis of data from June and July revealed hundreds of pharmaceutical shipments that entered the U.S. from facilities no one would expect, including unregistered Chinese exporters and alternative medicine clinics abroad.
Read More
The warning letter was one of about 100 is a new focus on deceptive direct-to-consumer drug advertisements.
Read More
The “green list” will help protect patients from unreliable, illegally compounded GLP-1s and simplify screening for border security.
Read More
PSM led a coalition of organizations urging leaders of the Senate HELP and House Energy and Commerce committees to help strengthen the FDA’s ability to protect Americans from unsafe and counterfeit medicines and medical products.
Read More
A decade ago no one had heard of deadly counterfeit prescription pills. Victims’ families bravely spoke up, lobbied, and rallied for change.
Read More
Chinese companies that supplied U.S. compounders have turned to making generic semaglutide for markets where Novo Nordisk’s main patent is expiring in 2026.
Read More
Elle published an exposé about bad actors and loose regulation in the medical spa industry.
Read More